The safety of itraconazole in the diabetic population

Journal of the American Podiatric Medical Association

Volumn 89, Issue 7, 1999, Pages 339-345

  Albreski, Douglas A ^a,b   Gross, Earl G ^a  

^a UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; ITRACONAZOLE;

AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; HUMAN; MALE; ONYCHOMYCOSIS; ORAL DRUG ADMINISTRATION; PALLIATIVE THERAPY; RANDOMIZED CONTROLLED TRIAL; SKIN DISEASE;

ADMINISTRATION, ORAL; AGED; ANTIFUNGAL AGENTS; DIABETES COMPLICATIONS; FEMALE; FOOT DERMATOSES; HUMANS; ITRACONAZOLE; MALE; ONYCHOMYCOSIS; PALLIATIVE CARE;

EID: 0033159814     PISSN: 87507315     EISSN: None     Source Type: Journal    
DOI: 10.7547/87507315-89-7-339     Document Type: Article

References (30)

1. LEVY LA: Epidemiology of onychomycosis in special-risk populations. JAPMA 87: 546, 1997.
2. GUPTA AK, KONNIKOV N, MACDONALD P, ET AL: Prevalence of onychomycosis in diabetics: a North American survey. Presented at the Fifty-sixth Annual Meeting of the American Academy of Dermatology, February 27-March 4, 1998, Orlando, FL.
3. US DEPARTMENT OF HEALTH AND HUMAN SERVICES: National Diabetes Fact Sheet: National Estimates and General Information on Diabetes in the United States, Centers for Disease Control and Prevention, Atlanta, 1997.
4. US DEPARTMENT OF HEALTH AND HUMAN SERVICES: Diabetes: A Serious Public Health Problem, Centers for Disease Control and Prevention, Atlanta, 1998.
5. SCHER RK: Onychomycosis is more than a cosmetic problem. Br J Dermatol 130 (suppl 43): 15, 1994.
6. ELEWSKI BE: The effect of toenail onychomycosis on patient quality of life. Int J Dermatol 36: 754, 1997.
7. SCHEIN JR, GAUSE D, LUBECK DP, ET AL: Onychomycosis: baseline results of an observational study. JAPMA 87: 512, 1997.
8. RICH P: Special patient populations: onychomycosis in the diabetic patient. J Am Acad Dermatol 35: S10, 1996.
9. REIBER GE, BOYKO EJ, SMITH DG: "Lower Extremity Foot Ulcers and Amputations in Diabetes," in Diabetes in America, 2nd Ed, ed by National Diabetes Data Group, p 409, National Institute of Diabetes and Kidney Diseases, Bethesda, MD, 1995.
10. ARMSTRONG DG, LAVERY LA, HARKLESS LB: Validation of a diabetic wound classification system. Diabetes Care 21: 855, 1998.
11. PECORARO RE, REIBER GE, BURGESS EM: Pathways to diabetic limb amputation: basis for prevention. Diabetes Care 13: 513, 1990.
12. AL FISHER ASSOCIATES, INC: 1997 Diabetes Survey: statistical results. JAPMA 87: 575, 1997.
13. EVANS SL, NIXON BP, LEE I, ET AL: The prevalence and nature of podiatric problems in elderly diabetic patients. J Am Geriatr Soc 39: 241, 1991.
14. LUGO-SOMOLINOS A, SANCHEZ JL: Prevalence of dermatophytes in patients with diabetes. J Am Acad Dermatol 26: 408, 1992.
15. BUXTON PK, MILNE LJR, PRESCOTT RJ, ET AL: The prevalence of dermatophyte infection in well-controlled diabetics and the response to Trichophyton antigen. Br J Dermatol 134: 900, 1996.
16. VAZQUEZ JA, SOBEL JD: Fungal infections in diabetics. Infect Dis Clin North Am 9: 97, 1995.
17. DEL ROSSO JQ, GUPTA AK: Oral antifungal agents: recognition and management of adverse reactions. Today's Therapeutic Trends 15: 75, 1997.
18. DEL Rosso JQ: Advances in the treatment of superficial fungal infections: focus on onychomycosis and dry tinea pedis. J Am Osteopath Assoc 97: 339, 1997.
19. Diflucan [package insert], Pfizer, Inc, New York.
20. Sporanox [package insert], Janssen Pharmaceutica, Titusville, NJ.
21. Lamisil [package insert], Novartis Pharmaceuticals Corp, East Hanover, NJ.
22. DEL ROSSO JQ, GUPTA AK: The spectrum of utility of oral antifungal agents: from the petri dish to the patient. Today's Therapeutic Trends 15: 179, 1997.
23. HEYKANTS J, MICHIELS M, MEULDERMANS W, ET AL: "The Pharmacokinetics of Itraconazole in Animals and Man: An Overview," in Recent Trends in the Discovery, Development and Evaluation of Antifungal Agents, ed by RA Fromtling, p 223, JR Prous Science Publishers, Barcelona, 1987.
24. HEYKANTS J, VAN PEER A, VAN DE VELDE V, ET AL: The clinical pharmacokinetics of itraconazole: an overview. Mycoses 32 (suppl 1): 67, 1989.
25. VERSPEELT J, DE DONCKER P, MARYNISSEN G, ET AL: Tolerability and safety of itraconazole in diabetics. Presented at the Fifty-sixth Annual Meeting of the American Academy of Dermatology, February 27-March 4, 1998, Orlando, FL.
26. MATTHIEU L, DE DONCKER P, CAUWENBERGH G, ET AL: Itraconazole penetrates the nail via the nail matrix and the nail bed - an investigation in onychomycosis. Clin Exper Dermatol 16: 374, 1991.
27. CAUWENBERGH G, DEGREEF H, HEYKANTS J, ET AL: Pharmacokinetic profile of orally administered itraconazole in human skin. J Am Acad Dermatol 18: 263, 1988.
28. DONCKER PD, GUPTA AK, MAEYNISSEN G, ET AL: Itraconazole pulse therapy for onychomycosis and dermatomycoses: an overview. J Am Acad Dermatol 37: 969, 1997.
29. DE DONCKER P, GUPTA AK, DEL ROSSO JQ, ET AL: Update on the safety of itraconazole pulse therapy in onychomycosis. Presented at the Fifty-sixth Annual Meeting of the American Academy of Dermatology, February 27-March 4, 1998, Orlando, FL.
30. HEALTH CARE FINANCING ADMINISTRATION: Health Care Provider News 39: 1998.